AstraZeneca (LON:AZN) PT Raised to £130

AstraZeneca (LON:AZN - Free Report) had its price objective increased by Berenberg Bank from £120 ($150.75) to £130 ($163.32) in a research note published on Friday morning, Marketbeat.com reports. Berenberg Bank currently has a buy rating on the biopharmaceutical company's stock.

A number of other equities research analysts have also weighed in on the stock. Deutsche Bank Aktiengesellschaft restated a hold rating and issued a £105 ($131.91) price objective on shares of AstraZeneca in a report on Tuesday, April 23rd. Barclays reissued an overweight rating and set a £125 ($157.04) target price on shares of AstraZeneca in a research report on Monday, April 8th. BMO Capital Markets restated an outperform rating on shares of AstraZeneca in a research report on Monday, February 12th. Jefferies Financial Group restated a hold rating and issued a £110 ($138.19) price objective on shares of AstraZeneca in a research note on Friday, February 16th. Finally, JPMorgan Chase & Co. reiterated an overweight rating on shares of AstraZeneca in a research report on Thursday, April 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus price target of £117.57 ($147.70).

AstraZeneca Stock Up 0.6 %

LON AZN traded up GBX 68 ($0.85) during trading hours on Friday, hitting £121.18 ($152.24). 2,560,495 shares of the company were exchanged, compared to its average volume of 2,210,976. The company has a 50 day moving average of £108.39 and a two-hundred day moving average of £105.07. The firm has a market cap of £187.83 billion, a price-to-earnings ratio of 3,751.70, a PEG ratio of 0.93 and a beta of 0.19. AstraZeneca has a 52-week low of GBX 9,461 ($118.86) and a 52-week high of £124.88 ($156.88). The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 92.51.

AstraZeneca Increases Dividend

The business also recently announced a dividend, which was paid on Monday, March 25th. Shareholders of record on Thursday, February 22nd were issued a GBX 156 ($1.96) dividend. The ex-dividend date of this dividend was Thursday, February 22nd. This is a boost from AstraZeneca's previous dividend of $71.80. This represents a yield of 1.49%. AstraZeneca's dividend payout ratio (DPR) is 7,058.82%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.